To compare the relative treatment effects of natalizumab and fingolimod in subgroups with relapsing-remitting multiple sclerosis
Latest Information Update: 11 Jun 2021
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 11 Jun 2021 New trial record
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology